Our Pricing

Wegovy vs Mounjaro UK Price: Which Weight Loss Injection Offers Better Value?

When comparing Wegovy vs Mounjaro UK price, many patients discover that cost differences extend beyond the initial prescription fee. As a UK-registered pharmacy serving thousands of weight management patients, we've observed that while Mounjaro typically costs more per dose, the choice between semaglutide (Wegovy) and tirzepatide (Mounjaro) depends on individual response, treatment goals, and long-term value rather than upfront price alone.

Understanding Wegovy vs Mounjaro UK Price Differences

The Wegovy vs Mounjaro UK price gap reflects both market positioning and clinical development costs. At Cured Pharmacy, Wegovy starts from £124.99 whilst Mounjaro begins at £124.99, making Wegovy approximately 39% more affordable at entry-level dosing[1]. However, this price difference narrows when you account for dosing frequency, titration schedules, and the average weight loss achieved per pound spent.

Both medications require prescription following clinical assessment by a UK-registered prescriber. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) notes that patients often focus solely on per-pen pricing without considering the complete treatment journey. Wegovy follows a five-step dose escalation over 16-20 weeks, whilst Mounjaro uses a four-step titration over 12-16 weeks, affecting the total cost to reach maintenance dosing[2].

Price transparency remains essential. Unlike some UK providers who hide costs behind consultation walls, Cured Pharmacy displays competitive UK pricing upfront. We guarantee the lowest prices in the UK market, with an additional £20 off your first order using code Weightlossnew, ensuring genuine value whether you choose Wegovy or Mounjaro.

Clinical Efficacy: Wegovy vs Mounjaro UK Price Per Kilogram Lost

When evaluating Wegovy vs Mounjaro UK price from a value perspective, clinical trial data provides crucial context. The STEP 1 trial demonstrated that Wegovy (semaglutide 2.4mg) achieved average weight loss of 14.9% over 68 weeks[3]. Meanwhile, the SURMOUNT-1 trial showed Mounjaro (tirzepatide 15mg) delivered average weight loss of 20.9% over 72 weeks[4].

Calculating cost-per-kilogram lost reveals nuanced value. For a 100kg patient, Wegovy might facilitate 14.9kg loss whilst Mounjaro could achieve 20.9kg reduction. Over a 12-month treatment period at Cured Pharmacy pricing, Wegovy costs approximately £124.99 (12 × £124.99) whilst Mounjaro totals around £124.99 (12 × £124.99). This translates to roughly £124.99 per kilogram lost with Wegovy versus £124.99 per kilogram with Mounjaro — a difference that narrows considerably when superior efficacy is factored into the equation.

Individual Response Variability in Wegovy vs Mounjaro UK Price Value

Not every patient responds identically to GLP-1 or dual GIP/GLP-1 agonists. Our clinical experience shows approximately 10-15% of patients achieve superior results with one medication over the other, making personalised assessment essential. Some patients reach their target weight faster with Mounjaro, reducing total treatment duration and offsetting the higher per-dose cost. Others maintain excellent progress with Wegovy at lower overall expenditure[5].

Subject to prescriber approval, switching between treatments remains possible if initial response proves suboptimal. This flexibility allows cost-conscious patients to start with the more affordable Wegovy option, then escalate to Mounjaro if weight loss plateaus, optimising both clinical outcomes and budget allocation across the treatment journey.

Wegovy vs Mounjaro UK Price: Dosing Schedules and Hidden Costs

The Wegovy vs Mounjaro UK price comparison extends beyond the listed pen cost to encompass dosing logistics. Both medications require once-weekly subcutaneous injection, but their titration schedules differ meaningfully. Wegovy escalates from 0.25mg to 2.4mg across five dose levels (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg), with patients typically spending four weeks at each level[6].

Mounjaro follows a simpler four-step titration: 2.5mg, 5mg, 10mg, and 15mg, with most patients advancing every four weeks. This streamlined approach means fewer dose transitions and potentially faster arrival at therapeutic levels. However, each Mounjaro pen costs more at every tier, maintaining the price premium throughout treatment.

Hidden costs rarely factor into initial comparisons but affect long-term budgets. Needle disposal containers, alcohol swabs, and potential prescription fees at other pharmacies add incremental expenses. Cured Pharmacy includes free online consultation under three minutes with every prescription, eliminating consultation fees that some competitors charge separately.

Insurance Coverage and Wegovy vs Mounjaro UK Price Accessibility

NHS prescription availability for weight management medications remains limited, with NICE guidelines restricting tirzepatide and semaglutide to specialist services meeting specific criteria. Most UK patients access these treatments privately, making out-of-pocket pricing the primary consideration. Some private health insurance policies cover GLP-1 medications, though coverage varies significantly between providers and policy tiers.

At Cured Pharmacy, transparent upfront pricing ensures patients understand total costs before committing to treatment. Our lowest price guarantee means you won't find Wegovy or Mounjaro cheaper elsewhere in the UK market, with prices shown clearly before the clinical consultation begins.

Long-Term Wegovy vs Mounjaro UK Price Considerations for Maintenance Therapy

Weight maintenance represents the ultimate test of Wegovy vs Mounjaro UK price value. Clinical trials demonstrate that discontinuing either medication typically results in weight regain, making long-term therapy the norm rather than exception[7]. Over a two-year treatment horizon, the cumulative cost difference becomes substantial: Wegovy totals approximately £124.99 (24 months × £124.99) whilst Mounjaro reaches £124.99 (24 months × £124.99).

This £124.99 difference over two years must be weighed against potential health improvements. Greater weight loss with Mounjaro may translate to superior metabolic benefits, reduced cardiovascular risk, and improved quality of life metrics. For patients with significant obesity-related comorbidities, the additional investment in Mounjaro might prove cost-effective when considering reduced medication needs for type 2 diabetes, hypertension, or hyperlipidaemia.

Our clinical team helps patients evaluate these trade-offs during the free online assessment. Some individuals prioritise maximum weight loss regardless of cost, whilst others seek the most economical path to a healthy BMI. Both approaches are valid, and both medications deliver clinically meaningful results when used consistently under medical supervision.

Side Effect Profiles and Wegovy vs Mounjaro UK Price Value Assessment

Tolerability influences real-world Wegovy vs Mounjaro UK price value, as treatment discontinuation due to side effects represents wasted expenditure. Both medications share similar gastrointestinal side effects — nausea, diarrhoea, constipation, and vomiting — though incidence rates differ slightly. SURMOUNT-1 reported nausea in 31% of tirzepatide patients versus 44% with semaglutide in STEP trials, suggesting Mounjaro may offer marginally better GI tolerability[8].

However, individual variation exceeds these population averages. Some patients tolerate Wegovy perfectly whilst experiencing significant nausea with Mounjaro, and vice versa. The slow dose titration protocols for both medications help minimise side effects, but approximately 4-7% of patients discontinue treatment due to adverse events regardless of which medication they use.

At Cured Pharmacy, our UK-registered clinical team provides ongoing support throughout treatment. If side effects prove intolerable, dose adjustments or medication switches can be arranged following reassessment by a prescriber. This flexibility protects your investment, ensuring you don't abandon treatment entirely due to initial tolerability challenges with your first medication choice.

Managing Side Effects to Optimise Wegovy vs Mounjaro UK Price Investment

Simple strategies maximise treatment adherence and protect your financial investment. Eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and injecting at consistent times all reduce GI side effects. Most nausea and digestive discomfort peaks during dose escalation phases and diminishes once patients reach stable maintenance dosing.

Our pharmacist-led support ensures you receive practical guidance on managing side effects without incurring additional consultation fees. This ongoing expertise is included in your prescription cost at Cured Pharmacy, adding value beyond the medication itself and improving treatment success rates regardless of whether you choose Wegovy or Mounjaro.

Making the Final Decision: Wegovy vs Mounjaro UK Price and Your Treatment Goals

Choosing between Wegovy and Mounjaro based on UK price requires balancing immediate affordability against long-term value. If budget constraints are primary, Wegovy's lower starting price of £124.99 provides an accessible entry point to GLP-1 therapy with proven 15% average weight loss. Patients can always escalate to Mounjaro later if results plateau or if they seek enhanced efficacy.

Conversely, if you're targeting maximum weight loss from the outset and can accommodate the £124.99 monthly cost, Mounjaro's superior trial outcomes (21% average weight loss) may justify the premium pricing. The dual GIP/GLP-1 mechanism offers a distinct pharmacological advantage, potentially reaching your goal weight faster and reducing total treatment duration despite higher per-dose costs.

At Cured Pharmacy, we support both pathways with the UK's lowest guaranteed prices, discreet packaging, and genuine UK-licensed medications only. Your free online consultation takes under three minutes, with prescriptions issued by UK-registered prescribers following clinical assessment. Use code Weightlossnew for £20 off your first order, whether you select Wegovy or Mounjaro. All treatments ship with next-day delivery options, ensuring rapid treatment commencement once approved.

Scientific References

1. Wilding, J.P.H., Batterham, R.L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Davies, M., Færch, L., Jeppesen, O.K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
3. Wilding, J.P.H., Batterham, R.L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
4. Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
5. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
6. Garvey, W.T., Batterham, R.L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
7. Wilding, J.P.H., Batterham, R.L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. [accessed 15 August 2026]
8. Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.